Journal of Cancer

The patient's condition improved and the event was considered to be resolved one day after onset without any further clinical concerns. The patient with the infusion related reaction was discontinued from the Phase 1 clinical trial in accordance with the protocol treatment stopping criteria defined for Grade 4 serious adverse events. ................
................